LC
Lineage Cell Therapeutics, Inc.
LCTX · AMEX
$1.02 -0.97% (-$0.01)
1M -4.63%
Market Cap $258.0M
P/E Ratio -
Div. Yield -
ROE 71.14%
Piotroski F-Score Weak
3/9Valuation
24 /100
Expensive P/S 19.72x
P/B 4.24x
P/E N/A
Growth
14 /100
Declining Rev. growth 0.33%
Book val. growth 15.31%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 96.59%
Net margin 246.58%
FCF margin 182.98%
Quality
2 /100
Poor ROIC 23.25%
ROE 71.14%
Asset turnover 0.12x
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 6.61x
Int. coverage N/A
Stability
8 /100
Unstable Beta 1.55x
Rev. volatility 46.20%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre LCTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Culley
Employees
75
Headquarters
Carlsbad
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report